EMA issues positive opinion for EUSA Pharma's Dinutuximab beta to treat neuroblastoma
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion in favour of marketing authorisation for EUSA Pharma's antibody ch14.18/CHO, Dinutuximab beta, to treat high-risk neuroblastoma …
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: European Medicines Agency (EMA) | Marketing | Neuroblastoma | Neurology | Pharmaceuticals